HANDOK Inc.

KOSE:A002390 Stock Report

Market Cap: ₩177.0b

HANDOK Valuation

Is A002390 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A002390 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A002390 (₩12860) is trading above our estimate of fair value (₩4857.66)

Significantly Below Fair Value: A002390 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A002390?

Key metric: As A002390 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A002390. This is calculated by dividing A002390's market cap by their current revenue.
What is A002390's PS Ratio?
PS Ratio0.3x
Sales₩512.66b
Market Cap₩177.00b

Price to Sales Ratio vs Peers

How does A002390's PS Ratio compare to its peers?

The above table shows the PS ratio for A002390 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.2x
A060590 CTCBIO
1.2xn/a₩169.5b
A011040 Kyung Dong Pharmaceutical
0.9xn/a₩164.6b
A271980 Jeil PharmaceuticalLtd
0.3xn/a₩183.5b
A032300 KOREA PHARMA
2.3xn/a₩182.8b
A002390 HANDOK
0.3xn/a₩177.0b

Price-To-Sales vs Peers: A002390 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does A002390's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$163.00m
A002620 Jeil Pharma Holdings
0.2xn/aUS$95.63m
A000230 Ildong Holdings
0.1xn/aUS$56.11m
No more companies available in this PS range
A002390 0.3xIndustry Avg. 0.8xNo. of Companies15PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A002390 is good value based on its Price-To-Sales Ratio (0.3x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A002390's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A002390 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A002390's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

7D

6.0%

1Y

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

7D

-3.4%

1Y

75.9%

Dong-A ST

₩544.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,300.00

7D

-2.0%

1Y

8.6%